ReWalk Robotics Ltd

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ReWalk Robotics reports robust Q1 results and plans for growth

ReWalk Robotics (LFWD) delivered strong Q1 2024 results, driven by Medicare claims approval and a focus on growth strategies.
Despite challenges in gross profit and operating expenses, the company's solid financial position and market development goals position it well for future success.
Opportunities lie in new product launches, increased interest in Medicare reimbursement, and strategic initiatives to drive revenue growth and profitability.

ReWalk Robotics reports record revenue in Q2 2024

ReWalk Robotics demonstrated strong financial performance in Q2 2024, driven by successful product placements and revenue growth.
While facing challenges in managing expenses and achieving gross margin targets, the company is well-positioned for future growth.
With a focus on innovation, market expansion, and cost efficiencies, ReWalk Robotics aims to capitalize on opportunities in the exoskeleton systems market.

ReWalk Robotics reports revenue growth and eyes profitability in 2025

ReWalk Robotics saw strong revenue growth in Q3 2024 driven by product sales.
Efforts to enhance operational efficiency and collaboration are key strengths.
Challenges include delays in sales due to Medicare cases and softness in clinic spending.
Opportunities lie in anticipated profitability in 2025 and continued revenue growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lifeward Ltd. is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm's exoskeletons provide hip and knee motion to enable individuals with spinal cord injury (SCI) to stand upright, walk, turn, and climb and descend stairs. Its products include ReWalk Exo-Suit and ReWalk Personal 6.0. The company was founded by Amit Goffer on June 20, 2001 and is headquartered in Marlborough, MA.

Lifeward's (LFWD) first-quarter 2024 results are expected to reflect the benefits of several milestone achievements from last year.

Should Lifeward (LFWD) be in Your Portfolio Ahead of Q1 Earnings?

ReWalk (LFWD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Bears are Losing Control Over ReWalk (LFWD), Here's Why It's a 'Buy' Now

Experienced healthcare and rehabilitation technology professional brings more than 30 years of experience in commercialization and new business development Experienced healthcare and rehabilitation technology professional brings more than 30 years of experience in commercialization and new business development

Lifeward Announces the Appointment of Mike Swinford to its Board of Directors

Finalized Medicare reimbursement pathway for personal exoskeletons expands access for all eligible Medicare beneficiaries Finalized Medicare reimbursement pathway for personal exoskeletons expands access for all eligible Medicare beneficiaries

Medicare Revises 2024 Fee Schedule to Include Payment Rate for the ReWalk Personal Exoskeleton

Cemex SAB de CV

SunCoke Energy

Opportunities frequently appear out of nowhere when underdog businesses triumph against the odds thanks to shrewd planning and forethought. The companies on this list all embody the spirit of the underdog, even though they operate in different industries.

Unleashing the Underdogs: 3 Hidden Gems Set to Conquer the Market

Collaboration with CMS on final payment rate focuses on commercial transaction values for the latest generation of ReWalk Exoskeleton

Lifeward CEO Issues Open Letter to Shareholders on Progress to Finalize Exoskeleton Medicare Payment Rate

Bicameral legislation seeks to codify annual examinations and assessments for assistive technologies, including Personal Exoskeletons, for Veterans with Spinal Cord Injury Bicameral legislation seeks to codify annual examinations and assessments for assistive technologies, including Personal Exoskeletons, for Veterans with Spinal Cord Injury

VA STAND Act introduced in the United States Senate

Deckers Outdoor

Post Holdings

Ralph Lauren

Invest in companies like Post Holdings (POST), ReWalk Robotics Ltd. (LFWD), Deckers Outdoor (DECK) and Ralph Lauren (RL) to make the most of their higher efficiency levels.

4 Must-Buy Efficient Stocks to Increase Your Portfolio Returns

Reverse split initiated to regain compliance with Nasdaq listing requirements Financial guidance for 2024 and profitability target for 2026 on existing capital remain unchanged MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd.

Lifeward Announces Reverse Share Split

Randomized clinical trial demonstrates significant improvements in walking ability for patients receiving therapy with the ReStore Exo-Suit as compared to a matched control group receiving conventional stroke therapy.

ReStore Exo-Suit Publications Demonstrate Improved Walking Outcomes Versus Conventional Stroke Therapy

The decision was communicated through CMS' bi-annual Healthcare Common Procedure Coding System (“HCPCS”) coding memorandum released yesterday; payment amount determination for ReWalk Personal Exoskeletons will continue to be on a case-by-case basis until such determination is finalized, likely later this year.

Lifeward announces the Centers for Medicare & Medicaid Services (“CMS”) is deferring its final decision on the payment rate for personal exoskeletons so that more recent claims information on the current, more advanced ReWalk Personal Exoskeleton may be c

Highest quarterly and annual revenue in the history of Lifeward Commercial and operational integration complete; synergies expected to yield $3 million in annual net savings

Lifeward Reports Fourth Quarter and Full Year 2023 Financial Results

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Feb. 20, 2024 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life's passions in the face of physical limitation or disability, today announced that the Company will release its fourth quarter and fiscal year-end 2023 financial results before the markets open on Tuesday, February 27, 2024.

Lifeward to Report Fourth Quarter and Fiscal Year-End 2023 Financial Results on February 27, 2024

ReWalk Robotics

Lifeward brand reflects the Company's commitment to pioneering innovative technology to empower the pursuit of life's ambitions in the face of physical limitation or disability

ReWalk Robotics Transforms Company Identity, Rebrands as Lifeward

News for ReWalk Robotics Ltd Stock (LFWD)